Alzheimer's disease therapeutics: New approaches to an ageing problem

IUBMB Life

Volumn 56, Issue 4, 2004, Pages 203-208

  Small, David H ^a   Losic, Dusan ^a   Martin, Lisandra L ^a   Turner, Bradley J ^b   Friedhuber, Anna ^b   Aguilar, Marie Isabel ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Amyloid; Cholesterol; Dementia; Immunotherapy; Nicotine; Secretase

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA AMYLOID ANTIBODY; BETA SECRETASE; BETA SECRETASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC AGENT; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOIDOSIS; BINDING AFFINITY; BINDING SITE; BRAIN CELL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME MECHANISM; HUMAN; IMMUNIZATION; IMMUNOPRECIPITATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; CARRIER PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECEPTORS, CELL SURFACE; RECEPTORS, NICOTINIC;

EID: 3042538415     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/15216540410001709211     Document Type: Review

References (26)

1. Taylor, J. P., Hardy, J., and Fischbeck, K. H. (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991-1995.
2. Small, D. H., and McLean, C. A. (1999) Alzheimer's disease and the amyloid beta protein: What is the role of amyloid? J. Neurochem. 73, 443-449.
3. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864-870.
4. Small, D. H., Mok, S. S., and Bornstein, J. C. (2001) Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2, 595-598.
5. Wolfe, M. S. (2002) Therapeutic strategies for Alzheimer's disease. Nat. Rev. Drug Dis. 1, 859-866.
6. Hadland, B. K., Manley, N. R., Su, D. M., Longmore, G. D., Moore, C. L., Wolfe, M. S., Schroeter, E. H., and Kopan, R. (2001) Gamma-secretase inhibitors repress thymocyte development. Proc. Natl. Acad. Sci. USA 98, 7487-7491.
7. Nunan, J., Shearman, M. S., Checler, F., Cappai, R., Evin, G., Beyreuther, K., Masters, C. L., and Small, D. H. (2001) The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur. J. Biochem. 268, 5329-5336.
8. Nunan, J., Williamson, N., Hill, A. F., Sernee, M. F., Masters, C. L., and Small, D. H. (2003) Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein. J. Neurosci. Res. 74, 378-385.
9. Schenk, D. (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824-828.
10. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
11. Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., and Weller, R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nature Med. 9, 448-452.
12. Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Muller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
13. Roher, A. E., Kuo, Y. M., Kokjohn, K. M., Emmerling, M. R., and Gracon, S. (1999) Amyloid and lipids in the pathology of Alzheimer disease. Amyloid 6, 136-145.
14. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
15. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443.
16. Refolo, L. M., Pappolla, M. A., LaFrancois, J., Malester, B., Schmidt, S. D., Thomas-Bryant, T., Tint, G. S., Wang, R., Mercken, M., Petanceska, S. S., et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8, 890-899.
17. Refolo, L. M., Pappolla, J., Malester, M. A., LaFrancois B., Thomas-Bryant, T., Wang, R., Tint, G. S., Sambamurti, K., and Duff, K. E. (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321-331.
18. Subasinghe, S., Unabia, S., Barrow, C. J., Mok, S. S., Aguilar, M. I., and Small, D. H. (2003) Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J. Neurochem. 84, 471-479.
19. Sargent, P. B. (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16, 403-443.
20. Kihara, T., Shimohama, S., Sawada, H., Kimura, J., Kume, T., Kochiyama, H., Maeda, T., and Akaike, A. (1997) Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann. Neurol. 42, 159-163.
21. Kihara, T., Shimohama, S., Urushitani, M., Sawada, H., Kimura, J., Kume, T., Maeda, T., and Akaike, A. (1998) Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res. 792, 331-334.
22. Peters, R., and McGee, R. (1982) Cigarette smoking and state-dependent memory. Psychopharmacology (Berl.) 76, 232-235.
23. Broide, R. S., and Leslie, F. M. (1999) The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol. Neurobiol. 20, 1-16.
24. Wang, H. Y., Li, W., Benedetti, N. J., and Lee, D. H. (2003) Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J. Biol. Chem. 278, 31547-31553.
25. Fodero, L. R., Mok, S. S., Losic, D., Martin, L. L., Aguilar, M. I., Barrow, C. J., Livett, B. G., and Small, D. H. (2004) Alpha7-nicotinic acetylcholine receptors mediate an Abeta1-42-induced increase in the level of acetylcholinesterase in primary cortical neurons. J. Neurochem. 88, 1186-1193.
26. Small, D. H., Fodero, L. R., Losic, D., Chu, C., Aguilar, M. I., Martin, L. L., and Chebib, M. (2004) Role of Aβ and the α7 nicotinic acetylcholine receptor in regulating synaptic plasticity in Alzheimer's disease. Lett. Pept. Sci. (in press).